Verona's first-in-class development candidate, ensifentrine (RPL554), has the potential to provide relief for patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), non-cystic fibrosis bronchiectasis (NCFBE), cystic fibrosis (CF) and asthma.
Ensifentrine is an inhaled therapy that acts as both a bronchodilator and an anti-inflammatory agent in one compound. This means, if approved, it would be the first single treatment that opens patients’ airways and reduces inflammation in the lungs.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze